Neurotoxicity related to valganciclovir in a child with impaired function: Usefulness of therapeutic drug monitoring

Annals of Pharmacotherapy

Volumn 40, Issue 1, 2006, Pages 143-146

  Peyrière, Hélène ^a   Jeziorsky, Eric ^b   Jalabert, Anne ^a   Cociglio, Marylène ^a   Benketira, Abdelkader ^b   Blayac, Jean Pierre ^a   Hansel, Sylvie ^a   Margueritte, Geneviève ^b   Hillaire Buys, Dominique ^a  

^a LAPEYRONIE HOSPITAL   (France)

^b HÔPITAL ARNAUD DE VILLENEUVE   (France)

Author keywords

Acyclovir; Neurotoxicity; Renal failure; Valganciclovir

Indexed keywords

ACICLOVIR; FUROSEMIDE; OMEPRAZOLE; PARACETAMOL; VALGANCICLOVIR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; CASE REPORT; CONFUSION; CONVALESCENCE; CREATININE CLEARANCE; CYTOMEGALOVIRUS INFECTION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG MONITORING; DRUG TOLERABILITY; DRUG WITHDRAWAL; HALLUCINATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; KIDNEY FAILURE; LEUKEMIA RELAPSE; MALE; NARANJO PROBABILITY SCALE; NEUROTOXICITY; PRIORITY JOURNAL; RATING SCALE; RETINITIS; SYMPTOMATOLOGY;

ADOLESCENT; ANTIVIRAL AGENTS; DRUG MONITORING; GANCICLOVIR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KIDNEY; KIDNEY DISEASES; LEUKEMIA, LYMPHOCYTIC, ACUTE; MALE; NEUROTOXICITY SYNDROMES;

EID: 32344451537     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1G214     Document Type: Article

References (17)

1. Stocchi R, Ward KN, Fanin R, Baccarani M, Apperley JF. Management of human cytomegalovirus infection and disease after allogeneic bone marrow transplantation. Haematologica 1999;84:71-9.
2. Curran M, Noble S. Valgancidovir. Drugs 2001;61:1145-50.
3. Markham A, Faulds D. Ganciclovir. An update of its therapeutic use in cytomegalovirus infection. Drugs 1994;48:455-84.
4. Cocohoba JM, McNicholl IR. Valganciclovir: an advance in cytomegalovirus therapeutics. Ann Pharmacother 2002;36:1075-9. DOI 10.1345/aph.1A393
5. Pescovitz MD, Rabkin J, Merion RM, et al. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant. Antimicrob Agents Chemother 2000;44:2811-5.
6. Jung D, Dorr A. Single-dose pharmacokinetics of valganciclovir in HIV- and CMV-seropositive subjects. J Clin Pharmacol 1999;39:800-4.
7. Paya C, Humar A, Dominguez E, et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004;4:611-20.
8. Cave H, Suciu S, Preudhomme C, et al. Clinical significance of HOX11L2 expression linked to t(5;14)(q35;q32), of HOX11 expression, and of SIL-TAL fusion in childhood T-cell malignancies: results of EORTC studies 58881 and 58951. Blood 2004;103:442-50.
9. Cociglio M, Peyrière H, Hillaire-Buys D, Alric R. Application of a standardized coextractive cleanup procedure to routine high-performance liquid chromatography assays of teicoplanin and ganciclovir in plasma. J Chromatogr B Biomed Sci Appl 1998;705:79-85.
10. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
11. Meeuwisse EJ, Groen FC, Dees A, Smit GH, Ottervanger JP. Lethargy with omeprazole (letter). BMJ 1997;314:481.
12. Ernst ME, Franey RJ. Acyclovir- and ganciclovir-induced neurotoxicity. Ann Pharmacother 1998;32:111-3. DOI 10.1345/aph.17135
13. Czock D, Scholle C, Rasche FM, Schaarschmidt D, Keller F. Pharmacokinetics of valganciclovir and ganciclovir in renal impairment. Clin Pharmacol Ther 2002;72:142-50.
14. Product information. Valcyte (valganciclovir). Nutley, NJ: Roche Pharmaceuticals, March 2001.
15. Clark BS, Chang IF, Karpen SJ. Valganciclovir for the prophylaxis of cytomegalovirus disease in pediatric liver transplant recipients (letter). Transplantation 2004;77:1480.
16. Burri M, Wiltshire H, Kahlert C, Wouters G, Rudin C. Oral valganciclovir in children: single dose pharmacokinetics in a six-year-old girl. Pediatr Infect Dis J 2004;23:263-6.
17. Brown F, Banken L, Saywell K, Arum I. Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositive volunteers. Clin Pharmacokinet 1999;37: 167-76.